RecruitingPhase 3NCT06952530
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)
Sponsor
Eli Lilly and Company
Enrollment
487 participants
Start Date
Apr 30, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- refer to the GZPL master protocol study for screening eligibility.
Exclusion Criteria1
- refer to the GZPL master protocol study for screening eligibility.
Interventions
DRUGOrforglipron
Administered orally
DRUGPlacebo
placebo administered
Locations(99)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06952530
Related Trials
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT0605963898 locations
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT070644731153 locations
Coaching and Navigation by Community Health Workers (CHWs) Through Telehealth for High-risk Hypertension
NCT074614154 locations
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
NCT052937561 location
SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism
NCT074820201 location